These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 19879152)
21. Role of angiotensin II in arterial pressure and renal hemodynamics in rats with altered renal development: age- and sex-dependent differences. Reverte V; Tapia A; Baile G; Gambini J; Gíménez I; Llinas MT; Salazar FJ Am J Physiol Renal Physiol; 2013 Jan; 304(1):F33-40. PubMed ID: 23097470 [TBL] [Abstract][Full Text] [Related]
22. Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats. Awad AS Vascul Pharmacol; 2006 Sep; 45(3):141-7. PubMed ID: 16959546 [TBL] [Abstract][Full Text] [Related]
23. Nitric oxide participates in the renal vasodilatory effect of candesartan in anesthetized rats. Demeilliers B; Mimran A; Jover B J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S208-12. PubMed ID: 9892165 [TBL] [Abstract][Full Text] [Related]
24. The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death. Mertens B; Varcin M; Michotte Y; Sarre S Eur J Neurosci; 2011 Oct; 34(7):1141-8. PubMed ID: 21936877 [TBL] [Abstract][Full Text] [Related]
25. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. Faure S; Bureau A; Oudart N; Javellaud J; Fournier A; Achard JM J Hypertens; 2008 Oct; 26(10):2008-15. PubMed ID: 18806625 [TBL] [Abstract][Full Text] [Related]
26. Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells. Yu Y; Jiang H; Niu Y; Zhang X; Zhang Y; Liu XI; Qi T; Yu C An Acad Bras Cienc; 2019; 91(2):e20180699. PubMed ID: 31038541 [TBL] [Abstract][Full Text] [Related]
27. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Banes AK; Shaw S; Jenkins J; Redd H; Amiri F; Pollock DM; Marrero MB Am J Physiol Renal Physiol; 2004 Apr; 286(4):F653-9. PubMed ID: 14678947 [TBL] [Abstract][Full Text] [Related]
28. Enzyme-assisted synthesis and structure characterization of glucuronic acid conjugates of losartan, candesartan, and zolarsartan. Alonen A; Jansson J; Kallonen S; Kiriazis A; Aitio O; Finel M; Kostiainen R Bioorg Chem; 2008 Jun; 36(3):148-55. PubMed ID: 18378273 [TBL] [Abstract][Full Text] [Related]
29. Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles. Zhang J; Wang JL; Yu WF; Zhou ZM; Tao WC; Wang YC; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH Eur J Med Chem; 2013 Nov; 69():44-54. PubMed ID: 24007859 [TBL] [Abstract][Full Text] [Related]
30. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. Vauquelin G; Fierens F; Van Liefde I J Hypertens Suppl; 2006 Mar; 24(1):S23-30. PubMed ID: 16601569 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Yang H; Hirooka K; Fukuda K; Shiraga F Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5800-4. PubMed ID: 19608537 [TBL] [Abstract][Full Text] [Related]
32. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447 [TBL] [Abstract][Full Text] [Related]
33. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. Huang Y; Bae SA; Zhu Z; Guo N; Roth BL; Laruelle M J Med Chem; 2005 Apr; 48(7):2559-70. PubMed ID: 15801845 [TBL] [Abstract][Full Text] [Related]
34. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335 [TBL] [Abstract][Full Text] [Related]
35. Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats. Gohlke P; Kox T; Jürgensen T; von Kügelgen S; Rascher W; Unger T; Culman J Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):477-83. PubMed ID: 12070762 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan. Chang JS; El-Gamal MI; Lee WS; Anbar HS; Chung HJ; Kim HI; Cho YJ; Lee BS; Lee SA; Moon JY; Lee DJ; Jeon HR; Lee J; Choi YW; Oh CH Eur J Med Chem; 2011 Sep; 46(9):3564-9. PubMed ID: 21641692 [TBL] [Abstract][Full Text] [Related]
37. The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells. Vauquelin G; Fierens FL; De Backer JP; Vanderheyden PM J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S15-7. PubMed ID: 9892135 [TBL] [Abstract][Full Text] [Related]
38. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. Brilla CG; Scheer C; Rupp H J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122 [TBL] [Abstract][Full Text] [Related]
39. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Ueki M; Koda M; Shimizu T; Mitsuta A; Yamamoto T; Murawaki Y Hepatogastroenterology; 2009; 56(93):1100-4. PubMed ID: 19760950 [TBL] [Abstract][Full Text] [Related]
40. Acute effects of candesartan on rat renal haemodynamics and proximal tubular reabsorption. Hiranyachattada S; Saetew S; Harris PJ Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):714-20. PubMed ID: 16173927 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]